|
Home
Page
Bella Mira Essential Oil
Supplements
Organic Carrier Oils
Diffusers
Bella Mira Skin Care
Essential Oil Information and Use
Express Order Form
Essential Oil
Singles
Essential Oil
Blends
Essential Oil
Kits
Essential Oil Supplies
Gluten Free Living and Recipes
Thyroid 101
Fibromyalgia 101
PAIN Relief and Information
Detoxification and Digestion Products
Pet Place
Save Your Computer Free Protection
CD's DVD's and Books
3-D Screensavers
Hormone Balance Test New
Improved
Thyroid Function Test
Internal Toxicity Test

Gift Certificates
Link Exchange/Banners
.gif)

Our
Shopping Cart Is:

& FAQ



| |
MRSA Now Resists Last-Chance Antibiotic
11-08-08
By: Jon Barron
MRSA, a virulent form of staph infection, has been giving the medical
community a workout as new, antibiotic-resistant strains keep developing.
Recently a new strain of MRSA has demonstrated resistance to the antibiotic
Zyvox, which was considered to be the one solution that would work when all
other antibiotics failed -- until now. Although "isolated" cases of Zyvox-resistance
have been reported in the past, in this case, 12 patients in the intensive care
unit of a hospital in Madrid, Spain, all developed MRSA that failed to respond
to the drug.
MRSA stands for methicillin-resistant Staphylococcus aureus, which indicates a
staph infection that has become resistant to penicillin. While other staph
infections easily succumb to antibiotics, MRSA infections don't. Although staph
bacteria live on the skin and typically cause no problems, infection can occur
when someone with a compromised immune system either breathes in the bacteria or
gets a skin wound through which staph bacteria enter the bloodstream. If the
invading bacteria happen to be antibiotic-resistant, the victim is in trouble.
One out of every five patients who develops an MRSA infection dies from it. In
2007, 95,000 new cases of MRSA were reported in the US, and 19,000 people lost
their lives from it. Eighty-five percent of those new MRSA infections originated
in hospital settings, where people with surgical wounds and compromised immune
systems crowd together, passing bacteria from one bed to the next.
The scientific community keeps working away to create a super-antibiotic that
MRSA won't become resistant to. Each time a new drug comes to market with
promises of invulnerability, it ends up like its predecessors -- powerless
against MRSA (or at least the next mutation of it). Although Zyvox-resistant
MRSA has so far manifested only in a very small number of patients, it's a good
bet that now that the bacteria has developed a resistant strain, it will spread.
That's certainly what's happened in the past. Before Zyvox, vancomycin was the
miracle drug that eventually stopped working.
Of course, it's no surprise that Zyvox has hit the therapeutic wall, though the
media and the medical world might act stupefied. As I've written before, where
antibiotics and bacteria collide, resistance is inevitable. Any population of
bacteria includes countless variants, so when an antibiotic kills the vulnerable
variants, those few strains that are resistant to the antibiotic multiply and
become stronger. The very act of using an antibiotic creates the opportunity for
strains resistant to it to flourish. Add to that the fact that bacteria can swap
genes, meaning that bacteria not only can develop a defense to antibiotics, but
they can mutate and teach other bacteria (of entirely different strains) how to
do the same thing. (That's actually very scary if you think about it.)
Because bacteria have a simple structure, they don't need to go through
sophisticated mutations to outsmart antibiotics, which are one-dimensional
weapons. If bacteria undergo just a simple change in a cell wall or in an
internal structure, the antibiotic no longer works. That's why combinations of
antibiotics sometimes work better than just a single drug. But combinations
merely delay the inevitable; they don't eliminate it. All of this means that the
more use an antibiotic gets, the more opportunity bacteria have to mutate and
become resistant.
It seems obvious that if bacteria can make simple changes that render
antibiotics useless, a more complex solution might work better -- something more
complex than combination shots, that is. Natural remedies usually contain scores
of active biochemicals that work together in countless combinations. For
instance, garlic contains allicin, a natural antibiotic that breaks down into
over 100 biologically active compounds. Any two of those compounds is the
equivalent of using two antibiotics -- any three compounds, three antibiotics --
etc. The bottom line is that using garlic alone is equivalent to using a
combination of 100 different antibiotics all at once. When you combine garlic
with other natural anti-pathogens such as ginger, onion, grapefruit seed
extract, olive leaf extract, and liquid ionic zinc, you create thousands and
thousands of combinations far too complex for a bacterium to evolve around.
But the pharmaceutical companies seemingly aren't that interested in complex,
effective, powerful natural remedies that lack side effects. Rather, they're
busily creating the next all-powerful antibiotic to replace Zyvox. So far, PTK
0796 leads the pack of potential new drugs, after demonstrating 98-percent
effectiveness against MRSA. There's also something called Iclaprim with a
93-percent success rate against MRSA skin infections, and ceftaroline, at 95
percent. All of these drugs are in experimental stages; all hold great promise
right now and will potentially wipe out a large number of staph infections
before becoming obsolete. But make no mistake, they will all become obsolete for
sure in short order, and will cause health-compromising side-effects along the
way.
Better to keep your immunity levels high by taking an immunity-boosting formula.
Stay out of hospitals if at all possible, and if you do feel an infection coming
on, take a natural antibiotic cocktail.
Search MRSA
Search Strep
Search Staph
Search Antibiotics
|